Osimertinib (AZD9291)

Catalog No.S7297

Osimertinib (AZD9291) Chemical Structure

Molecular Weight(MW): 499.61

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 135 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Lysates from MGH121 parental cells treated with 1 μM of the indicated TKIs except for AZD9291 (160 nM) for 6 hours were probed with the indicated antibodies.

    Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560 . Osimertinib (AZD9291) purchased from Selleck.

    Western blot analysis for total (t-) and phosphorylated (p-) EGFR, AKT, ERK1/2, and β actin in H1975 parental and resistant (COR#3, AZDR#1) cells.

    Cancer Res, 2017, 77(8):2078-2089. Osimertinib (AZD9291) purchased from Selleck.

  • F, PC-9/ffluc and PC-9/LMC-GR cells (2×103 cells/well) were incubated with various concentrations of osimertinib for 72 hours. Cell viability was determined by MTT assay. Bars represent SD of quadruplicate cultures. Data shown are representative of three independent experiments with similar results.

    Mol Cancer Ther, 2017, 16(3):506-515. Osimertinib (AZD9291) purchased from Selleck.

    Western blot analysis showing phospho-EGFR (p-EGFR), total EGFR, phospho-ERK (p-ERK), total ERK, phospho-AKT (p-AKT), total AKT and β-actin as a loading control in H1975 cells treated with the indicated inhibitors. Equivalent amounts of proteins from whole cell lysates were subjected to WB analysis to detect the indicated proteins.

    J Biol Chem, 2015, 290(28): 17495-504. Osimertinib (AZD9291) purchased from Selleck.

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Features Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
L858R/T790M EGFR [1]
(LoVo cells)
Exon 19 deletion EGFR [1]
(LoVo cells)
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
In vitro

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC9 GR4 M1LPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMVExKM7:TR?= NXLrbVR6PzJiaB?= Mkm1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2q2WVI2QTR6NkOz
PC9 NEHjVZpHfW6ldHnvckBCe3OjeR?= M3vTfVAuOTBizszN M33RflczKGh? NWHFcmxncW6qaXLpeJMhX1RiRVfGVkBifCCub4egZ49v[2WwdILheIlwdnN? Ml;2NlU6PDh4M{O=
PC9 GR4 M2jUOmZ2dmO2aX;uJGF{e2G7 NYLNOG0xOC1zMDFOwG0> MXO3NkBp M2jySolvcGmkaYTzxsBGT0[UIIDoc5NxcG:{eXzheIlwdiCjbnSg[I94dnO2cnXhcUB{cWewYXzpcofDqA>? M2PqelI2QTR6NkOz
VP-2 NV3kOIxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\PTVUxKG6P MUixNEBl NIGzRYFFVVOR NIWxUnlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO= NXvsW|VsOjV2N{ezNlU>
PC-9/ERc1 NVXuVYJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKzRXJnPTBibl2= M1rxSVExKGR? NEW4NpNFVVOR MmjPbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm| NVHINWh5OjV2N{ezNlU>
PC-9/BRc1 NIK5bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jvPVUxKG6P MXuxNEBl NWrSRVI6TE2VTx?= MmTvbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm| MlnHNlU1Pzd|MkW=
VP-2 NWDHWXRUTnWwY4Tpc44hSXO|YYm= NEnyNlM2OCCwTR?= NVXZVIpTOjRiaB?= NES0OFBFVVOR MV;pcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= NX3oc5A6OjV2N{ezNlU>
PC-9/ERc1 MnXKSpVv[3Srb36gRZN{[Xl? MnHGOVAhdk1? NEHuZmczPCCq NYrpdoNsTE2VTx?= MmHybY5lfWOnczDlfJBz\XO|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2= MkfLNlU1Pzd|MkW=
PC-9/BRc1 NGewbGpHfW6ldHnvckBCe3OjeR?= MWm1NEBvVQ>? NF:wO3gzPCCq NF20clFFVVOR M2[5Solv\HWlZYOg[ZhxemW|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN NW\QPFJIOjV2N{ezNlU>

... Click to View More Cell Line Experimental Data

In vivo AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]


Animal Research:


+ Expand
  • Animal Models: Mice bearing PC9 and H1975 xenograft tumors
  • Formulation: --
  • Dosages: ~5 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 99 mg/mL warmed (198.15 mM)
Ethanol 43 mg/mL warmed (86.06 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 499.61

C28 H33 N7 O2

CAS No. 1421373-65-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02923947 Not yet recruiting Solid Tumours AstraZeneca|Quintiles, Inc. January 2017 Phase 1
NCT02972333 Not yet recruiting EGFR-TKI Resistant Mutation|Nonsmall Cell Lung Cancer|AZD9291|Brain Metastases Shandong Cancer Hospital and Institute|AstraZeneca December 2016 Phase 3
NCT02997501 Recruiting Lung Cancer AstraZeneca|TigerMed December 2016 Phase 3
NCT02771314 Recruiting Non Small Cell Lung Cancer Hellenic Oncology Research Group June 2016 Phase 2
NCT02811354 Not yet recruiting Carcinoma, Non-Small-Cell Lung National University Hospital, Singapore|AstraZeneca|Singapore Clinical Research Institute June 2016 Phase 2
NCT02736513 Recruiting Lung Cancer Rabin Medical Center May 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • Answer:

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFR Signaling Pathway Map

Related EGFR Products

Tags: buy Osimertinib (AZD9291) | Osimertinib (AZD9291) supplier | purchase Osimertinib (AZD9291) | Osimertinib (AZD9291) cost | Osimertinib (AZD9291) manufacturer | order Osimertinib (AZD9291) | Osimertinib (AZD9291) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID